Literature DB >> 32048150

Prediction model of human ABCC2/MRP2 efflux pump inhibitors: a QSAR study.

Minh-Tri Le1,2, Thien-Vy Phan3, Viet-Khoa Tran-Nguyen1, Thanh-Dao Tran1, Khac-Minh Thai4.   

Abstract

The overexpression of ABCC2/MRP2, an ATP-binding cassette transporter, contributes to multidrug resistance in cancer cells. In this study, a quantitative structure-activity relationship (QSAR) analysis on ABCC2 inhibitors has been carried out, aiming to establish a computational prediction model for ABCC2 modulators. Seven classification models and two regression models were built by SONNIA 4.2, and two other regression models were built by MOE 2008.10 based on a data set comprising 372 compounds collected from 16 relevant publications. The CPG-C iABCC2 model for classifying ABCC2 inhibitors has total accuracy of 0.88 and Matthews correlation coefficient MCC = 0.75. The CPG-C iEG model for classifying ABCC2 inhibitors (substrate EG: β-estradiol 17-β-D-glucuronide) has total accuracy of 0.91 and MCC = 0.82. The regression model PLS EG-IC50 for predicting ABCC2 inhibitors (substrate EG) gave root-mean-square error RMSE = 0.26, Q2 = 0.73 and [Formula: see text]. The regression model PLS CDCF-IC50 for predicting ABCC2 inhibitors [substrate CDCF: 5(6)-carboxy-2',7'-dichlorofluorescein] gave RMSE = 0.31, Q2 = 0.74 and [Formula: see text]. Four 2D-QSAR models were applied to 1661 compounds, with results indicating 369 compounds having the ability to reverse the efflux of both EG and CDCF by ABCC2, 152 among them having IC50 < 100 µM.

Entities:  

Keywords:  ABCC2; Classification; Inhibitor; QSAR; Regression; Virtual screening

Year:  2020        PMID: 32048150     DOI: 10.1007/s11030-020-10047-9

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  21 in total

1.  Impact of probe compound in MRP2 vesicular transport assays.

Authors:  Heidi Kidron; Gloria Wissel; Nenad Manevski; Marika Häkli; Raimo A Ketola; Moshe Finel; Marjo Yliperttula; Henri Xhaard; Arto Urtti
Journal:  Eur J Pharm Sci       Date:  2012-03-03       Impact factor: 4.384

2.  Physicochemical parameters responsible for the affinity of methotrexate analogs for rat canalicular multispecific organic anion transporter (cMOAT/MRP2).

Authors:  Y H Han; Y Kato; M Haramura; M Ohta; H Matsuoka; Y Sugiyama
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

3.  ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2.

Authors:  G Jedlitschky; I Leier; U Buchholz; J Hummel-Eisenbeiss; B Burchell; D Keppler
Journal:  Biochem J       Date:  1997-10-01       Impact factor: 3.857

4.  Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport.

Authors:  Azza A K El-Sheikh; Jeroen J M W van den Heuvel; Jan B Koenderink; Frans G M Russel
Journal:  J Pharmacol Exp Ther       Date:  2006-09-27       Impact factor: 4.030

Review 5.  Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition.

Authors:  Gabriele Jedlitschky; Ulrich Hoffmann; Heyo K Kroemer
Journal:  Expert Opin Drug Metab Toxicol       Date:  2006-06       Impact factor: 4.481

Review 6.  Emerging transporters of clinical importance: an update from the International Transporter Consortium.

Authors:  K M Hillgren; D Keppler; A A Zur; K M Giacomini; B Stieger; C E Cass; L Zhang
Journal:  Clin Pharmacol Ther       Date:  2013-04-08       Impact factor: 6.875

7.  Characterization of 5(6)-carboxy-2,'7'-dichlorofluorescein transport by MRP2 and utilization of this substrate as a fluorescent surrogate for LTC4.

Authors:  Krisztina Heredi-Szabo; Emese Kis; Eva Molnar; Andras Gyorfi; Peter Krajcsi
Journal:  J Biomol Screen       Date:  2008-03-18

Review 8.  Advancement of structure-activity relationship of multidrug resistance-associated protein 2 interactions.

Authors:  Li Xing; Yiding Hu; Yurong Lai
Journal:  AAPS J       Date:  2009-06-03       Impact factor: 4.009

9.  Compound profiling for ABCC2 (MRP2) using a fluorescent microplate assay system.

Authors:  Frank Förster; Astrid Volz; Gert Fricker
Journal:  Eur J Pharm Biopharm       Date:  2007-10-09       Impact factor: 5.571

10.  Support vector machine and pharmacophore-based prediction models of multidrug-resistance protein 2 (MRP2) inhibitors.

Authors:  Hui Zhang; Ming-Li Xiang; Ying-Lan Zhao; Yu-Quan Wei; Sheng-Yong Yang
Journal:  Eur J Pharm Sci       Date:  2008-12-11       Impact factor: 4.384

View more
  2 in total

1.  Literature review and report of three cases of Dubin-Johnson syndrome related to ABCC2 gene mutations in children.

Authors:  Sheng-Jie You; Ying-Xue Sun; Jing Zhang; Qiang He; Xiao-Ming Wu; Yan Hu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

2.  Adenosine triphosphate-binding cassette subfamily C members in liver hepatocellular carcinoma: Bioinformatics-driven prognostic value.

Authors:  Xiangtong Meng; Shen Dong; Liu Yangyang; Song Wang; Xiaohao Xu; Tiejun Liu; Xiong Zhuang
Journal:  Medicine (Baltimore)       Date:  2022-02-18       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.